Cargando…

A new interspinous process distraction device BacFuse in the treatment of lumbar spinal stenosis with 5 years follow-up study

To explore a suitable indication of interspinous process distraction device for lumbar spinal stenosis with BacFuse. Patients of lumbar spinal stenosis (LSS) who experienced interspinous process distraction device surgery with BacFuse from June 2014 to January 2015 in our institute were included. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Mengmeng, Tang, Hai, Shan, Jianlin, Chen, Hao, Jia, Pu, Bao, Li, Feng, Fei, Shi, Guan, Wang, Ruideng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329017/
https://www.ncbi.nlm.nih.gov/pubmed/32590804
http://dx.doi.org/10.1097/MD.0000000000020925
_version_ 1783552835267330048
author Chen, Mengmeng
Tang, Hai
Shan, Jianlin
Chen, Hao
Jia, Pu
Bao, Li
Feng, Fei
Shi, Guan
Wang, Ruideng
author_facet Chen, Mengmeng
Tang, Hai
Shan, Jianlin
Chen, Hao
Jia, Pu
Bao, Li
Feng, Fei
Shi, Guan
Wang, Ruideng
author_sort Chen, Mengmeng
collection PubMed
description To explore a suitable indication of interspinous process distraction device for lumbar spinal stenosis with BacFuse. Patients of lumbar spinal stenosis (LSS) who experienced interspinous process distraction device surgery with BacFuse from June 2014 to January 2015 in our institute were included. We classified LSS into central and lateral types, and then divided these into severe and moderate according to the degree of stenosis. Each type was divided into 2 groups. Patients in group A underwent distraction without bone decompression (stand-alone), while patients in group B underwent bone decompression combined with distraction. Follow-up was performed at 1 month, 3 months, 6 months, 2 years, and 5 years after surgery. Zurich Claudication Questionnaire (ZCQ) was recorded to assess the patient's postoperative condition at each follow-up. A total of 142 patients were available for follow up at each time interval. There was a significant difference between the preoperative and final follow-up ZCQ scores for every LSS type. In addition, there was no difference between group A and group B in the postoperative ZCQ scores with the exception of the lateral severe type. In the study, 22 of the 23 patients (95.65%) in the lateral moderate type were considered to have a satisfactory result in group B, with a similar result of 93.33% (14/15) in group A (P = .75). In the lateral severe type, the patient satisfaction rate was 65.22% (15/23) and 90.63% (29/32) in group A and group B (P = .02), respectively. In the central moderate type, the patient satisfaction rate was 81.82% (15/23) and 76.92% (10/13) in group A and group B (P = .77), respectively. Satisfaction rate for the follow-up results in the central severe type reached 57.14% (4/7) in group A, and 54.55% (6/11) in group B (P = .91). Moreover, no relationship was found between satisfaction and neurogenic intermittent claudication. The most suitable indication for BacFuse treatment was the lateral moderate type. For lateral severe patients, distraction combined with decompression is suggested for a higher satisfaction rate. Severe central spinal stenosis was shown to be a relative contraindication for BacFuse.
format Online
Article
Text
id pubmed-7329017
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-73290172020-07-09 A new interspinous process distraction device BacFuse in the treatment of lumbar spinal stenosis with 5 years follow-up study Chen, Mengmeng Tang, Hai Shan, Jianlin Chen, Hao Jia, Pu Bao, Li Feng, Fei Shi, Guan Wang, Ruideng Medicine (Baltimore) 7100 To explore a suitable indication of interspinous process distraction device for lumbar spinal stenosis with BacFuse. Patients of lumbar spinal stenosis (LSS) who experienced interspinous process distraction device surgery with BacFuse from June 2014 to January 2015 in our institute were included. We classified LSS into central and lateral types, and then divided these into severe and moderate according to the degree of stenosis. Each type was divided into 2 groups. Patients in group A underwent distraction without bone decompression (stand-alone), while patients in group B underwent bone decompression combined with distraction. Follow-up was performed at 1 month, 3 months, 6 months, 2 years, and 5 years after surgery. Zurich Claudication Questionnaire (ZCQ) was recorded to assess the patient's postoperative condition at each follow-up. A total of 142 patients were available for follow up at each time interval. There was a significant difference between the preoperative and final follow-up ZCQ scores for every LSS type. In addition, there was no difference between group A and group B in the postoperative ZCQ scores with the exception of the lateral severe type. In the study, 22 of the 23 patients (95.65%) in the lateral moderate type were considered to have a satisfactory result in group B, with a similar result of 93.33% (14/15) in group A (P = .75). In the lateral severe type, the patient satisfaction rate was 65.22% (15/23) and 90.63% (29/32) in group A and group B (P = .02), respectively. In the central moderate type, the patient satisfaction rate was 81.82% (15/23) and 76.92% (10/13) in group A and group B (P = .77), respectively. Satisfaction rate for the follow-up results in the central severe type reached 57.14% (4/7) in group A, and 54.55% (6/11) in group B (P = .91). Moreover, no relationship was found between satisfaction and neurogenic intermittent claudication. The most suitable indication for BacFuse treatment was the lateral moderate type. For lateral severe patients, distraction combined with decompression is suggested for a higher satisfaction rate. Severe central spinal stenosis was shown to be a relative contraindication for BacFuse. Wolters Kluwer Health 2020-06-26 /pmc/articles/PMC7329017/ /pubmed/32590804 http://dx.doi.org/10.1097/MD.0000000000020925 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 7100
Chen, Mengmeng
Tang, Hai
Shan, Jianlin
Chen, Hao
Jia, Pu
Bao, Li
Feng, Fei
Shi, Guan
Wang, Ruideng
A new interspinous process distraction device BacFuse in the treatment of lumbar spinal stenosis with 5 years follow-up study
title A new interspinous process distraction device BacFuse in the treatment of lumbar spinal stenosis with 5 years follow-up study
title_full A new interspinous process distraction device BacFuse in the treatment of lumbar spinal stenosis with 5 years follow-up study
title_fullStr A new interspinous process distraction device BacFuse in the treatment of lumbar spinal stenosis with 5 years follow-up study
title_full_unstemmed A new interspinous process distraction device BacFuse in the treatment of lumbar spinal stenosis with 5 years follow-up study
title_short A new interspinous process distraction device BacFuse in the treatment of lumbar spinal stenosis with 5 years follow-up study
title_sort new interspinous process distraction device bacfuse in the treatment of lumbar spinal stenosis with 5 years follow-up study
topic 7100
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329017/
https://www.ncbi.nlm.nih.gov/pubmed/32590804
http://dx.doi.org/10.1097/MD.0000000000020925
work_keys_str_mv AT chenmengmeng anewinterspinousprocessdistractiondevicebacfuseinthetreatmentoflumbarspinalstenosiswith5yearsfollowupstudy
AT tanghai anewinterspinousprocessdistractiondevicebacfuseinthetreatmentoflumbarspinalstenosiswith5yearsfollowupstudy
AT shanjianlin anewinterspinousprocessdistractiondevicebacfuseinthetreatmentoflumbarspinalstenosiswith5yearsfollowupstudy
AT chenhao anewinterspinousprocessdistractiondevicebacfuseinthetreatmentoflumbarspinalstenosiswith5yearsfollowupstudy
AT jiapu anewinterspinousprocessdistractiondevicebacfuseinthetreatmentoflumbarspinalstenosiswith5yearsfollowupstudy
AT baoli anewinterspinousprocessdistractiondevicebacfuseinthetreatmentoflumbarspinalstenosiswith5yearsfollowupstudy
AT fengfei anewinterspinousprocessdistractiondevicebacfuseinthetreatmentoflumbarspinalstenosiswith5yearsfollowupstudy
AT shiguan anewinterspinousprocessdistractiondevicebacfuseinthetreatmentoflumbarspinalstenosiswith5yearsfollowupstudy
AT wangruideng anewinterspinousprocessdistractiondevicebacfuseinthetreatmentoflumbarspinalstenosiswith5yearsfollowupstudy
AT chenmengmeng newinterspinousprocessdistractiondevicebacfuseinthetreatmentoflumbarspinalstenosiswith5yearsfollowupstudy
AT tanghai newinterspinousprocessdistractiondevicebacfuseinthetreatmentoflumbarspinalstenosiswith5yearsfollowupstudy
AT shanjianlin newinterspinousprocessdistractiondevicebacfuseinthetreatmentoflumbarspinalstenosiswith5yearsfollowupstudy
AT chenhao newinterspinousprocessdistractiondevicebacfuseinthetreatmentoflumbarspinalstenosiswith5yearsfollowupstudy
AT jiapu newinterspinousprocessdistractiondevicebacfuseinthetreatmentoflumbarspinalstenosiswith5yearsfollowupstudy
AT baoli newinterspinousprocessdistractiondevicebacfuseinthetreatmentoflumbarspinalstenosiswith5yearsfollowupstudy
AT fengfei newinterspinousprocessdistractiondevicebacfuseinthetreatmentoflumbarspinalstenosiswith5yearsfollowupstudy
AT shiguan newinterspinousprocessdistractiondevicebacfuseinthetreatmentoflumbarspinalstenosiswith5yearsfollowupstudy
AT wangruideng newinterspinousprocessdistractiondevicebacfuseinthetreatmentoflumbarspinalstenosiswith5yearsfollowupstudy